A carregar...
伊布替尼联合CAR-T治疗BCL-2抑制剂耐药伴del(17p)慢性淋巴细胞白血病一例报告并文献复习
OBJECTIVE: To improve the knowledge and experience of ibrutinib combined with CAR-T cells in the treatment of high-risk chronic lymphoblastic leukemia (CLL) patients or small lymphocytic lymphoma (SLL) with TP53 gene aberration. METHODS: One case of del (17p) CLL patients with BCL-2 inhibitor resist...
Na minha lista:
| Publicado no: | Zhonghua Xue Ye Xue Za Zhi |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Editorial office of Chinese Journal of Hematology
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7342441/ https://ncbi.nlm.nih.gov/pubmed/31648477 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.09.008 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|